Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · IEX Real-Time Price · USD
14.61
-0.76 (-4.94%)
Jul 22, 2024, 9:26 AM EDT - Market open
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
67
Market Cap
402.99M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 210.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionANRO News
- 6 days ago - Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder - Business Wire
- 4 weeks ago - Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia - Business Wire
- 4 weeks ago - Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner - Business Wire
- 7 weeks ago - Alto Neuroscience to Present at the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer - Business Wire
- 2 months ago - Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences - Business Wire
- 3 months ago - Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia - Business Wire